MedTrace Logo

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

NCT02253251 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2025-01-23

No results posted yet for this study

Summary

The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.

Conditions

Interventions

GENETIC

KRAS-variant and microRNA binding site mutation testing

Participant in these studies will be tested for the KRAS-variant

Sponsors & Collaborators

  • MiraKind

    lead OTHER

Principal Investigators

  • Joanne Weidhaas, MDPhD · MiraKind

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2030-12-31
Completion
2035-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02253251 on ClinicalTrials.gov